INTRODUCTION: We aimed at evaluating the efficacy and durability of a lopinavir/ritonavir-based dual regimen (LPV/r-DR) in virologically controlled HIV-infected individuals in current clinical practice. METHODS: Patients who have initiated for the first time a LPV/r-DR with HIV-RNA<50 copies/mL were included in this observational study. The main endpoints were: time to virological rebound [VR=time of first of two consecutive viral loads (VL)>50 copies/mL] and time to experience either a single VL>200 copies/mL or discontinuation/intensification (= treatment failure, TF). Individuals' follow-up accrued from the date of starting the LPV/r-DR to event or last available VL. Kaplan-Meier curves and Cox regression analysis were used. Covariates included in the multivariable analysis were gender, age, route of transmission, hepatitis co-infection, calendar year of starting the DR, nadir CD4+ count, VL at initiation of first cART, previous failures to protease inhibitors (PIs), time with undetectable VL before starting the DR and the type of DR [nucleoside reverse transcriptase (NRTI), non-NRTI (NNRTI), raltegravir or maraviroc, with NRTI as reference group]. RESULTS are presented as median (Q1, Q3) or frequency (%) as appropriate. RESULTS: 108 individuals followed for 18 (7, 30) months were included; baseline (BL) characteristics are detailed in Table 1. CONCLUSIONS: A LPV/r-DR can be considered a valuable option in patients with HIV-RNA<50 copies/mL and ongoing toxicity from the third drug of the regimen, although up to 17% of patients showed viral rebound by 3 years. Older patients are at lower risk of failure with this strategy, but larger sample size is needed to identify who might benefit from this strategy instead of others.

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting / Gianotti, N; Cozzi Lepri, A; Antinori, A; Di Biagio, A; Moioli, Mc; Nozza, S; Cingolani, A; De Luca, A; Madeddu, Giordano; Bonora, S; Ceccherini Silberstein, F; Monforte, Ad; ICONA Foundation, Study. - In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. - ISSN 1758-2652. - 2:17 (4 Suppl 3)(2014), p. 19799. [10.7448/IAS.17.4.19799]

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting.

MADEDDU, Giordano;
2014

Abstract

INTRODUCTION: We aimed at evaluating the efficacy and durability of a lopinavir/ritonavir-based dual regimen (LPV/r-DR) in virologically controlled HIV-infected individuals in current clinical practice. METHODS: Patients who have initiated for the first time a LPV/r-DR with HIV-RNA<50 copies/mL were included in this observational study. The main endpoints were: time to virological rebound [VR=time of first of two consecutive viral loads (VL)>50 copies/mL] and time to experience either a single VL>200 copies/mL or discontinuation/intensification (= treatment failure, TF). Individuals' follow-up accrued from the date of starting the LPV/r-DR to event or last available VL. Kaplan-Meier curves and Cox regression analysis were used. Covariates included in the multivariable analysis were gender, age, route of transmission, hepatitis co-infection, calendar year of starting the DR, nadir CD4+ count, VL at initiation of first cART, previous failures to protease inhibitors (PIs), time with undetectable VL before starting the DR and the type of DR [nucleoside reverse transcriptase (NRTI), non-NRTI (NNRTI), raltegravir or maraviroc, with NRTI as reference group]. RESULTS are presented as median (Q1, Q3) or frequency (%) as appropriate. RESULTS: 108 individuals followed for 18 (7, 30) months were included; baseline (BL) characteristics are detailed in Table 1. CONCLUSIONS: A LPV/r-DR can be considered a valuable option in patients with HIV-RNA<50 copies/mL and ongoing toxicity from the third drug of the regimen, although up to 17% of patients showed viral rebound by 3 years. Older patients are at lower risk of failure with this strategy, but larger sample size is needed to identify who might benefit from this strategy instead of others.
Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting / Gianotti, N; Cozzi Lepri, A; Antinori, A; Di Biagio, A; Moioli, Mc; Nozza, S; Cingolani, A; De Luca, A; Madeddu, Giordano; Bonora, S; Ceccherini Silberstein, F; Monforte, Ad; ICONA Foundation, Study. - In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. - ISSN 1758-2652. - 2:17 (4 Suppl 3)(2014), p. 19799. [10.7448/IAS.17.4.19799]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/69414
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact